Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo in Participants With Resistant Hypertension [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating LCI699 versus placebo in resistant hypertension completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• LCI699 (LCI699)

Snippet

Sponsor: Novartis | Conditions: Hypertension | Phase 2 | Status: COMPLETED | Results posted: 2021-06-02